Pipeline insights for chronic spontaneous urticaria, DelveInsight
According to DelveInsight analysis, the chronic spontaneous urticaria (CSU) pipeline consists of more than 20 leading companies actively developing more than 20 treatments for CSU.
Overview of Chronic Spontaneous Urticaria:
Urticaria, commonly known as hives, wheals, or nettle rash, is characterized by itchy, red, and swollen skin. Chronic spontaneous urticaria (CSU) is a type of urticaria in which hives last for more than 6 weeks, usually occurring on most days of the week. CSU often presents with widespread wheals and may be accompanied by angioedema. Diagnosis is based on a history of daily or episodic urticaria lasting less than 24 hours without an identifiable physical trigger. International guidelines recommend limited diagnostic testing, primarily including differential blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Common treatments for CSU include antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.
For a detailed analysis report on the Chronic Spontaneous Urticaria pipeline, please see below:https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report
DelveInsight's pipeline report on chronic spontaneous urticaria paints a dynamic landscape with over 20 active players working on 20+ pipeline therapies for the treatment of CSU. Key players in the chronic spontaneous urticaria space, including United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceutical Co., ValenzaBio, Carna Biosciences, Servier, and others, are exploring novel drug candidates for CSU to improve treatment options. Notable pipeline therapies at various stages of development include dupilumab, tezepelumab, valzovolimab, and others.
Recent Developments in the Chronic Spontaneous Urticaria Pipeline Segment:
- In November 2024, the U.S. Food and Drug Administration (FDA) accepted the resubmission of a supplemental biologics license application (sBLA) for Dupixent for the treatment of patients aged 12 years and older with CSU inadequately controlled with H1 antihistamines. The application is supported by data from the LIBERTY-CUPID Phase 3 clinical trial showing a significant reduction in itch and urticaria activity. An FDA decision is expected by April 18, 2025.
- In November 2024, Incyte stopped enrollment in its study of INCB000262 in patients with CSU because toxicological issues were identified in clinical testing, despite no adverse events being observed in ongoing trials, which may impact future development.
- In March 2024, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Omuriclo, a biosimilar to Xolair (omalizumab), for severe allergic asthma, severe chronic rhinosinusitis with nasal polyps, and CSU. Omuriclo received marketing authorization in the European Union in May 2024, providing a new treatment option for patients with CSU.
- In November 2023, Novartis announced that remibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, showed a significant reduction in urticaria activity compared to placebo in a Phase III study, demonstrating its potential as an effective oral treatment for CSU.
Chronic Spontaneous Urticaria Pipeline Analysis:
This report provides insights into:
- Detailed information on the key companies developing treatments in the Chronic Spontaneous Urticaria market.
- Evaluating therapeutic candidates in early, mid and late stages of development for CSU treatment.
- An analysis of companies involved in the development of targeted therapeutics, focusing on both active and inactive (dormant or discontinued) projects.
- Overview of emerging medicines in development based on stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
- It offers an in-depth analysis of collaborations (both corporate-to-corporate and corporate-to-academic), licensing agreements, and funding details for future advancements in the Chronic Spontaneous Urticaria market.
For a free sample page of the Chronic Spontaneous Urticaria Pipeline report, please visit:https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
New drugs for chronic spontaneous urticaria:
- Dupilumab: Sanofi
- Tezepelumab: Amgen
- Valzolvolimab: Celldex Therapeutics
Key Players in the Chronic Spontaneous Urticaria Segment:
Currently, over 20 leading companies are developing treatments for chronic spontaneous urticaria, of which Sanofi has the most advanced drug candidate, currently in the pre-registration stage.
The DelveInsight report includes details on approximately 20+ products at various stages of clinical development, including:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early Stage Products (Phase I)Together
- Preclinical and discovery stage candidates
- Discontinued and inactive candidates
The Chronic Spontaneous Urticaria Pipeline report provides a therapeutic assessment of pipeline drugs based on route of administration. The products are classified based on different routes of administration (ROA) as follows:
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
The products are categorized based on the type of molecule:
- Monoclonal antibodies
- Low molecular weight
- peptide
To download a detailed assessment of new treatments and key companies, please visit: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
Chronic Spontaneous Urticaria Pipeline Treatment Evaluation:
- Rating chronic spontaneous urticaria by product type
- Evaluation by developmental stage
- Evaluation by route of administration
- Evaluation by molecular type
For more information regarding the Chronic Spontaneous Urticaria Treatment market, download the sample report here @:Treatment evaluation of chronic spontaneous urticaria
table of contents
- Introduction to the report
- Executive Summary
- Current treatment patterns for chronic spontaneous urticaria
- Chronic Spontaneous Urticaria – A DelveInsight Analytical Perspective
- Treatment evaluation
- Chronic spontaneous urticaria late stage product (Phase III)
- Chronic spontaneous urticaria mid-stage product (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage products
- Inactive Products
- Dormant products
- Chronic Spontaneous Urticaria Discontinued Products
- Chronic Spontaneous Urticaria Product Profile
- Major players in Chronic Spontaneous Urticaria
- Main products for chronic spontaneous urticaria
- Inactive and Discontinued Products
- Unmet Needs in Chronic Spontaneous Urticaria
- Future prospects for chronic spontaneous urticaria
- Analyst review of chronic spontaneous urticaria
- Appendix
- Reporting Methods
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
English
Dutch